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1. Abstract: 
 
Background: Pituitary adenomas (PA) are rare with an incidence of 0.4 – 8.2 per 105 
inhabitants. Symptoms range from headaches to pituitary insufficiency or excessive output 
of hormones with associated disease. Except for prolactinomas, surgery is recommended 
as first line and most effective treatment for the majority of these tumors. One of the 
refinements of surgical therapy introduced was intraoperative magnetic resonance 
imaging (iMRI). 
Objective: The aim of this study was analyzing the postoperative pituitary function and the 
general outcome of patients treated for non-functioning and GH-producing PAs with a 
transsphenoidal iMRI-assisted approach using the PoleStar™ N20 imager. 
Methods: 148 consecutive iMRI-guided surgeries for GH-producing and non-functioning 
PAs were retrospectively analyzed. Patients' clinical data, endocrinological parameters, 
clinical examinations and pre-/post- and intraoperative imaging studies were evaluated. 
Results: 101 patients could be classified as being in remission at follow-up; 26 (17.6%) of 
them due to iMRI allowing additional tumor removal. 44 patients (29.7%) had more 
complete tumor removal because remnants were detected by iMRI. 
The mean hormone levels of patients did not differ significantly between pre- and 
postoperative examinations. There were 62 patients with preoperative- and 43 patients 
with postoperative pituitary insufficiency, thus, due to surgery there were 19 (12.8%) 
patients with improved pituitary function. 
Conclusions: The results show this method to be a safe and effective treatment option 
increasing remission rate and keeping complication rate low. Postoperative pituitary 
function was being preserved or improved - possibly due to more exact iMRI-assisted 
tumor removal. 
 
Keywords:  
Acromegaly, PoleStar™ N20, intraoperative magnetic resonance tomography, MRI, iMRI, 
pituitary adenoma, transsphenoidal surgery, non-functioning pituitary adenoma, 
endocrinological outcome, endocrinology 
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2. Introduction: 
 
Pituitary adenomas (PA) are rare neoplasm with an estimated incidence of 0.4 – 8.2 per 
105 inhabitants (1,2,3). Symptoms range from headache and cranial nerve palsy – being 
signs of elevated intracranial pressure or direct compression of neural structures (4,5) - to 
endocrinological deficiency or excessive output of hormones with associated disease 
(6,7). Diagnosis is usually established by computed tomography (CT) or magnetic 
resonance imaging (MRI) performed for investigation of neurological symptoms or 
endocrinological disturbances and endocrinological examination including hormone blood 
levels. 
 
Acromegaly is a rare disease with an estimated incidence of about 4 per 106 inhabitants. 
In most cases, it is caused by a growth-hormone (GH)-producing pituitary adenoma (PA). 
If excessive output of GH is not normalized, severe cardiovascular and metabolic 
disturbances as well as cosmetic and orthopaedic deformities will result. Previously 
published studies have shown a 2-3-fold increased mortality for treatment-resistant cases 
as compared to successfully treated patients and healthy individuals (8,9,10). Correction 
of GH values to normal can restore life expectancy towards normal. First surgical 
treatment using a transnasal approach in an acromegalic patient was performed by Dr. 
Schloffer in Vienna in 1907 (11).  
 
Non-functioning pituitary adenomas (NFPAs) add up to (nowadays 30-50% of all 
macroadenomas) 25-30% of all PAs with an estimated incidence of 0.1 – 3.0 per 105 
inhabitants (7,12,13). The symptoms of NFPAs are caused by the tumor’s mass effect, 
which results in headache due to stretching of the diaphragma sellae and the sellar dura 
and visual deficits due to chiasmal compression. Diplopia may occur as a result of lateral 
tumor growth and/or hemorrhage into the cavernous sinus. In addition, patients can 
develop symptoms of secondary pituitary insufficiency due to compression of the pituitary 
gland (6,7). Visual disturbances occur in 53.8-74% (4,5) headaches in 9.7-56% (4,14), 
and third nerve palsy in 12% (4). 
 
Except for asymptomatic micro-PAs and for prolactinomas, surgery is generally 
recommended as treatment of choice (1,6,15,16,17,18,19,20,21). As most pituitary 
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adenomas are benign neoplasms, tumor control can be achieved by complete resection. 
Today, most patients receive surgery as first line treatment using a transnasal, 
transsphenoidal approach introduced by Cushing (22) and reintroduced using 
microsurgical techniques by Hardy in 1979 (23). In cases successfully treated by surgery, 
the outcome is defined by persisting neurological syptoms and pituitary function. A 
requirement for hormone replacement therapy is associated with the inconvenience of 
daily medication and regular tests whether the treatment is appropriate; moreover, 
hormone substitution is also an important socioeconomic factor as replacement therapy 
can generate costs being a multiple of the initial surgical treatment. 
In recent years there have been a lot of refinements in the surgical treatment of PA like 
improvement of endoscopy and introduction of intraoperative magnetic resonance imaging 
(iMRI) (21,24,25,26,27,28,29,30,31,32,33). Those treatment options have been analyzed 
regarding the clinical outcome and tumor control and showed superior results in the 
treatment of certain PAs (i.e. Growth hormone producing PA) compared to the 
conventional surgical approach. Endocrinological outcome has only been a minor part in 
those studies as the research focus concentrated mainly on tumor control.  
 
In this largest study to date we analysed the postoperative pituitary function and the 
general outcome of 148 consecutive surgical procedures for non-functioning and GH-
producing PAs being treated using a transnasal, transsphenoidal microsurgical iMRI-
assisted approach using the PoleStar N20 imager. 
 
 
3. Patients and methods 
 
3.1. Patient demographics (Table 1): 
One-hundred-forty-eight surgical procedures were performed in 145 patients (82 male, 63 
female) suffering from non-functioning- or GH-producing PA between September 2005 
and August 2009. Thirty-nine patients presented with GH-producing PA and 109 patients 
with NFPA. Three patients (1 male, 2 female) underwent surgery twice for removal of 
recurrent tumor. All patients were being operated by the senior author R.L.B. using the 
same standardized transsphenoidal approach with the aid of ultra low-field iMR imaging. 
The mean patient age was 55±15 years (range 19–80 years). The median preoperative 
tumor volume was 6797 mm3 (range 50–65,450 mm3; mean diameters 
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23mm*20mm*19mm). Ten cases (6.9%) presented with microadenomas, 118 (82.5%) 
with macroadenomas, and 15 (10.5%) with giant adenomas. 24 patients (17.1%) had 
previous pituitary surgery. In 51 cases (35.7%) the tumor invaded the cavernosus sinus. 
Overall, 89 patients (62.2%) had cranial nerve symptoms, among them 79 (55.2%) with 
visual field deficits. 56 patients (37.8%) complained about headache. In 37 out of the 39 
cases (94.8%) with GH-producing PA, patients had symptoms of acromegaly. 
 
3.2. Pre- and postoperative management: 
Patients were seen as outpatients before surgery. After decision for surgical treatment, 
patients arrived in hospital the day before surgery. Preoperative diagnostics included 
computed tomography (CT) scan and magnetic resonance imaging (MRI) for 
determination of the pituitary adenoma, bony and neurovascular structures. Pre- and 
postoperative imaging studies were performed at the Department of Neuroradiology, 
University Hospital of Zurich. CT studies were performed on a 16 slice CT scanner 
(Siemens SOMATON® Sensation, München, Germany) acquiring non contrast-enhanced 
and contrast-enhanced multi slice imaging data. The MRI studies were performed on a 1.5 
Tesla MR tomography scanner (Signa®, General Electric, Milwaukee, USA). 
Neurological and ophthalmological examinations were performed after admission. General 
patient data, additional diagnosis, medication at admission and previous study results 
were noted. Patients underwent endocrinological examination which included blood 
analysis for pituitary function examining growth hormone (GH), insulin-like growth factor-1 
(IGF-1), adrenocorticotropin (ACTH), cortisol, thyroid stimulating hormone (TSH), fT4, fT3, 
prolactin, luteinizing hormone (LH), follicle stimulating hormone (FSH) and human 
chorionic gonadotropin (hCG); testosterone was measured in male and estradiol in female 
patients unless a history of recent menstrual bleedings or of contraceptive pill intake was 
given. 
Patients signed written consent for the surgical procedure and general anaesthesia. At the 
day of surgery, patients with reduced Cortisol plasma levels received 100mg 
hydrocortisone (SoluCortef®, Pfizer, New York City, USA) one hour before operation, and. 
another dose of 100mg hydrocortisone was given perioperatively. After surgery, patients 
were transferred to intermediate care unit (IMCU). A postoperative CT scan was 
performed in all patients around six hours after surgery to exclude major bleeding or 
serious complications. The next morning patients were transferred to the general ward 
and mobilized. They received 100mg of hydrocortisone on the first and 50mg on the 
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second postoperative day. On the morning of the third operative day and/or before 
discharge, pituitary function was re-examined. If patients' cortisol levels were below 
200nmol./l in early morning blood samples, they received 30mg of hydrocortisone 
(Hydrocortone®, Merck, Darmstadt, Germany) per day until endocrinological follow-up as 
outpatients four weeks after surgery. 
 
3.3. Surgery and intraoperative neuroimaging: 
All operations were performed in general anaesthesia. Patients were put in supine 
position on a foldable standard operation table with their head slightly reclined. The head 
was then fixed in a MRI-compatible head holder after adjusting the radio frequency coil 
around the patients head. The iMRI scanner used in all patients was a PoleStar™ N20 
(0.15 Tesla, Medtronic Navigation, Louisville, CO, USA). Afterwards the intraoperative 
navigation system (Stealth Station, Medtronic Navigation, Louisville, CO, USA) was 
referenced with preoperative CT studies. The position of the patient’s head in the scanner 
was tested by performing a 24 second sagittal e-steady scan (8mm slices) and adjusted if 
necessary. Before surgery, a 7-minute, T1-weighted, gadolinium (20 ml Dotarem®, 
Guerbet, Roissy CdG Cedex, France) enhanced, 4mm slice, coronal iMRI scan was 
performed. These images were automatically loaded into the navigation system and 
merged with the preoperative imaging studies. 
All parts of surgical procedures were performed by using an operating microscope 
(Pentero®, Carl Zeiss, Oberkochen, Germany). At the beginning of operations a self-
retaining endonasal speculum was inserted in the nostril chosen for surgical approach. 
The mucosa was incised and partially removed, the posterior bony part of the septum was 
removed and the anterior wall of the sphenoid sinus was displayed. The anterior wall of 
the sphenoid sinus was then opened with punches, the intrasphenoidal mucosa and 
septum were removed and the inferior and anterior surface of the sella was displayed and 
opened with a chisel. The dura mater was opened in an x-shaped fashion and the 
adenoma removed by curettes, grasping forceps and suction devices. Tumor material was 
sent for frozen sections and neurohistopathological examination. After complete tumor 
removal according to the surgeon’s impression, a 3.5-minute, T1-weighted, gadolinium- 
enhanced, 4mm slice, coronal iMRI scan was performed for resection control in all 
patients. For better visualisation of possible tumor remnants, a glove-covered ball of bone 
wax was inserted into the resection cavity for hemostasis and improved interpretation of 
intraoperative images. The intraoperatively acquired images were automatically merged 
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with the existing preoperative and intraoperative imaging studies. In cases of visible tumor 
remnant, the resection cavity was re-examined and tumor remnants removed if possible. 
Another post-resectional, intraoperative 3.5-minute, T1-weighted, gadolinium- enhanced, 
4mm slice, coronal iMRI scan was performed in those cases. The anterior wall of the sella 
turcica was reconstructed by using the extracted posterior part of the bony nasal or 
intrasphenoidal septum. In cases of intraoperative CSF leakage, the sella was packed 
with abdominal fat and use of fibrin sealant. No nasal packing was used. All operations 
were performed by the senior author. 
 
3.4. Follow-up: 
All patients were followed-up four weeks postoperatively as outpatients in the 
endocrinology clinic; hormone levels were analyzed and deficiencies replaced if 
necessary. Three months after surgery, patients received a postoperative MRI study for 
resection control and patients were seen for neurosurgical follow up and examination. 
 
3.5. Statistical analysis and neuroimaging: 
The statistical analysis was performed using Microsoft Excel (Version 2003) and SPSS 
Statistic software (Version 16.0). All imaging studies were analyzed independently and 
blinded to the clinical outcome using standardized software (picture archiving and 
communication system, PACS). Tumor volume was calculated based on the diameter 
method (Tumor volume = 4/3 * Pi * ½x * ½y * ½z), where x, y and z are the maximum 
diameters in the three axis. 
 
 
4. Results 
 
4.1. Intraoperative imaging: (Table 2) 
On average, 2.51± 0.99 intraoperative imaging studies were acquired per patient; the first 
at the beginning of the surgical procedure for mapping with the preoperative high-field 
MRI and a CT study, and another scan was performed before closure to confirm tumor 
removal and to check for tumor remnant. Based on these images, 44 patients (29.7%) 
received further tumor removal since tumor remnants were detected. In this case, at least 
one further imaging study was made to check for further tumor remnant. The other 98 
patients (66.2%) showed no sign of tumor remnant (86 patients) unless visible tumor 
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remnant was left in place (12 patients) due to predictably high risk of complications in 
case of further tumor removal. There was a rate of patients being in remission during the 
overall follow-up in this study of 75.5% within the group of patients not undergoing further 
tumor removal and of 59.1% in the group undergoing further tumor removal. There were 
an additional 26 patients (17.6% of study group) being in remission during follow-up due 
to intraoperative imaging that lead to complete adenoma resection. 
 
4.2. Neurodiological follow-up: (Table 2) 
Patients were seen for clinical and neuroradiological follow-up (1.5 Tesla MRI) at three 
months after surgery. There was another MRI performed one year postoperatively, and 
further imaging studies during overall follow-up in case of visible tumor remnant, tumor 
regrowth or newly developed symptoms. Overall mean follow-up during this study was 32 
month (range 4-62 month). 
There were 106 patients considered tumor remnant-free, and 101 of them were 
considered in remission. The remaining 5 patients underwent surgery for GHPA and 
postoperatively complained about persisting symptoms of acromegaly and suffered from 
elevated GH levels without showing tumor remnant in postoperative high-field MRI. 
There were 42 patients with postoperative tumor remnant visible in postoperative high-
field follow-up MRI. The mean volume of tumor remant was 1191mm3 (range 4-
15559mm3). The tumor volume could be reduced to around one sixth of the preoperative 
size (6797mm3 (range 50-65,450mm3)) in those patients. 
 
4.3 Early postoperative course and complications: 
Patients were hospitalized for a mean (mit range eher median geben als mean) time of 9 
days (range 5-79 days). Six patients needed temporary lumbar drainage and one patient a 
temporary external ventricular drainage due to postoperative cerebrospinal fluid (CSF) 
fistula. Ten patients developed postoperatve transient diabetes insipidus (DI) with the 
need of temporary treatment with desmopressin during hospitalization of which one 
needed permanent medication. Eight patients developed temporary SIADH within the first 
24 days after surgical treatment with need for further or ongoing hospitalization. Three 
patients needed transsphenoidal revision surgery for CSF fistula with associated 
meningitis and one for CSF fistula alone. 
9 
 
Two patients died during the study period for reasons considered unrelated to the surgical 
procedure (one for unknown reasons 11 months after surgery at an age of 87 years, one 
for pneumonia at an age of 59 years 2 months after surgery). 
 
4.4. Endocrinological outcome: 
Patients underwent endocrinological examination pre and postoperatively (Table 3). The 
mean hormone levels of cortisol, TSH, fT4, GH, IGF1 and prolactin did not differ 
significantly between the pre- and the postoperative condition. Mean cortisol level in 
nmol/l was 393 (3-1640) and 349 (9-808); mean TSH level in mU/l was 1.73 (0.01-6.96) 
and 1.72 (0.01-6.12); mean fT4 level in pmol/l was 13.80 (5.60-20.30) and 15.35 (4.00-
25.40); mean GH level in NFPA patients in ug/l was 0.59 (0.05-4.88) and 1.21 (0.08-5.55); 
mean IGF1 level in NFPA patients in ug/l was 102 (31-492) and 101 (29-209) and mean 
prolactin level in ug/l was 25.07 (0.50-109.50) preoperatively and 15.38 (0.50-227.00) 
postoperatively . 
 
Before surgery, 62 patients (41.9%) were found with partial or total pituitary insufficiency 
of which only 30 patients (48.4%) received preoperative hormone substitution therapy – in 
many cases due to the short time between diagnosis and surgery (Table 4); GH deficiency 
was usually not sought by provocative tests and is therefore underreported. 38 (61.3%) of 
these 62 patients had persisting pituitary insufficiency, with need for ongoing hormone 
replacement therapy after surgery, but in 25 patients (38.7%) postoperative examinations 
showed full recovery of pituitary function without signs of insufficiency or further need for 
substitution therapy. 21 out of these 25 patients (87.5%) were patients with NFPAs 
without previous pituitary surgery who underwent further tumor removal due to 
intraoperative imaging. There were statistically no significant differences in Hardys 
classification of these patients. 
Among the 62 patients with preoperative pituitary insufficiency, 22 (35.5%) had a PA 
invading the cavernous sinus. In the group with postoperatively persisting insufficiency, 14 
patients (36.8%) had preoperative tumor infiltration of cavernous sinus. In the group with 
full recovery of pituitary function the rate was roughly the same with 8 patients (33.3%) 
showing infiltration of cavernous sinus. 
 
In contrast to the above mentioned group with full recovery of pituitary function, there were 
13 patients (8.8%) who developed pituitary insufficiency after surgery and required (at 
10 
 
least temporarily) hormone substitution therapy. All these patients had NFPAs. Five of 
them were in need of permanent hormone substitution therapy. These five patients were 
all considered not being in remission after surgical procedures during this study. 
Interestingly there was not one single case with first time pituitary surgery and 
postoperative newly developed persisting pituitary insufficiency. Only one of them showed 
PA infiltration of cavernous sinus in preoperative imaging. 
 
Analysis of pituitary function in patients grouped according to the PA’s Hardy classification 
of their adenoma revealed that those in class D and E were more severely affected than 
those in classes A, B and C. Before surgery we found pituitary insufficiency in 10 patients 
(30.3%) of class A, in 24 patients (42.1%) of class B, in 10 patients (30.3%) of class C, in 
11 patients (68.7%) of class D and in 7 patients (77.8%) of class E. In all those groups 
roughly half of the patients were on hormone substitution therapy when admitted to 
hospital for surgical treatment – 5 patients (15.1%) of class A, 12 patients (21.0%) of class 
B, 6 patients (18.2%) of class C, 5 patients (31.2%) of class D and 3 patients (33.3%) of 
class E. 
After surgery, improving pituitary function was more often observed than deterioration, i.e. 
overall, disappearance of pituitary insufficiency was more common than development of 
pituitary failure. 24 patients with insufficiency at baseline no longer needed hormone 
substitution therapy after surgery: – 6 (18.2%) of class A, 8 (14.0%) of class B, 4 (12.1%) 
of class C, 5 (31.2%) of class D and 1 (11.1%) of class E according to Hardys 
classification. 
On the other hand, 13 patients, considered sufficient at baseline, developed pituitary 
insufficiency after surgery. Five of them suffered from permanent insufficiency and 
remained dependent on long term hormone replacement therapy – 2 (6.1%) of class A 
and 3 (5.3%) of class B according to Hardys classification. 
 
The remission rates in the different patient groups were 72.7% for class A, 77.2% for class 
B, 69.7% for class C, 25.0% for class D and 66.6% for class E according to Hardys 
classification. 
 
Overall, there were 62 patients with pituitary insufficiency before surgery; 30 of them were 
on hormone replacement treatment. Overall, there were 43 patients with postoperative 
pituitary insufficiency and need for ongoing hormone substitution therapy – 5 with newly 
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developed insufficiency postoperatively and 38 with persisting insufficiency. Therefore, 
surgical treatment resulted in a net decrease of 19 patients who were in need for medical 
treatment in the postoperative as compared to the preoperative condition; – 30.6% of the 
patients with preoperative pituitary insufficiency and 12.8% of the complete study 
population. 
 
4.5. Clinical outcome: 
Patients were seen at three months follow-up for clinical-neurological examination. Out of 
56 patients complaining about headache before surgery, 38 patients (67.8%) reported 
complete regression, 5 patients (8.9%) improvement and 13 patients (23.2%) unchanged 
pain. Regarding visual field deficits there was a complete regression found in 55 patients 
(69.6%), an improvement in 14 patients (17.7%) and unchanged symptoms in 10 patients 
(12.6%). 
 
 
5. Illustrative Case: 
A forty-two year old female was admitted for resection of a large pituitary adenoma. She 
complained about headache, amenorrhea and galactorrhea. Endocrinological diagnosis 
revealed a panhypopituitarism. The patient underwent surgery and the non-functioning 
pituitary adenoma could be totally removed. Postoperative follow-up showed normal 
pituitary function and the patient is in remission for 48 month by now. The figures show 
preoperative imaging, intraoperative imaging with various stages of the tumor resection 
and postoperative follow-up MRI. 
 
 
 
 
 
 
 
 
6. Discussion: 
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In this largest study to date we analyzed the postoperative outcome, neurological 
symptoms and postoperative pituitary function in 148 patients undergoing iMRI-assisted 
transsphenoidal surgery for GH-producing- and NFPAs. 
The overall remission rate during a mean follow-up of 32 months (4-62) was 101 out of 
148 patients (68.2%) applying the remission criteria of the latest international consensus 
conference regarding the GH-producing PAs and not detectable tumor remnant or 
regrowth in neuroradiological follow-up with high-field MRI in patients with NFPA. These 
results are as least as good as previously published series reporting remission rates 
between 25 and 70% (5,27,34,35,36,37,38,39,40,41). Comparison remains difficult as 
most of the series included all kind of PAs but did not include giant adenomas, and 
remission criteria differed widely. 
Our results show that pituitary function was preserved in most of the patients as there 
were only 5 patients (3.4%) showing postoperative pituitary insufficiency and need for 
permanent medical treatment which is in accordance with the literature showing rates 
ranging from 5.6% to 30.0% (42). Mean hormone values showed no significant differences 
between pre- and postoperative endocrinological examinations in this study. 
Adenoma resections even led to complete recovery of pituitary function in 24 patients so 
that overall, 19 patients (12.8%) less remained dependent on permanent substitution 
therapy. Comparison with other published series is difficult as patient groups, type of 
included adenoma and other study parameters differ widely. 
 
Interestingly, remission rates were not related to postoperative need for further hormone 
substitution – which was already been shown in the literature (42). Among the patients 
with preoperative pituitary insufficiency, 36 patients were in remission while 26 patients 
were not. There was no need for further hormone substitution in 14 out of these 36 
patients (38.9%) and in 10 out of those 26 patients (38.5%). 
 
The surgical method used appeared safe as only a minor number of patients suffered 
complications. There were only four patients with need for reoperation because of CSF 
fistula and no patients with neurological deterioration due to surgery. The two deaths (one 
due to pneumonia) within the study population were considered unrelated to the surgical 
procedure. This all adds up to a remarkably low rate of complications compared to the 
literature; particularly when considering that 15 patients with giant adenomas were 
included (24,43,44,45). 
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Our results show that previous pituitary surgery elevates the risk of postoperative newly 
diagnosed pituitary insufficiency as all patients with new need for postoperative hormone 
substitution therapy had revision surgery for tumor regrowth or remnant. Interestingly 
those 5 patients (3.4%) had tumors of Hardy classification A or B only, which means that 
tumor size seems to be less of a risk factor for newly developing postoperative pituitary 
insufficiency. Out of 124 patients with first time pituitary surgery there was not a single 
case with postoperative newly developed pituitary insufficiency but 5 out of 24 patients 
with revision surgery showed newly developed pituitary insufficiency. Another factor 
explaining these results is that patients with Hardy classification D and E had a higher 
percentage of pituitary insufficiency already before surgery (72.2%) compared to Hardy 
classification A, B and C patients (24.4%). 
 
Cavernous sinus infiltration of PAs seems to be a sign of greater tumor expansion but 
interestingly did not lead to higher rates of pituitary insufficiency, possibly since this does 
not mean more compression of healthy pituitary tissue in all cases. There were only 
35.5% of patients with preoperative pituitary insufficiency showing cavernous sinus 
infiltration. In the complete study population there were 50 patients (33.8%) with 
cavernous sinus infiltration as well. Out of the 38 patients with postoperative persisting 
pituitary insufficiency there were 14 patients (36.8%) with cavernous sinus infiltration and 
out of the 24 patients with no further pituitary insufficiency there were 8 patients (33.3%) 
with cavernous sinus infiltration. These results suggest that cavernous sinus infiltration is 
not a  risk factor for pituitary insufficiency. 
 
There were some general limitations in this study that need to be thought of. iMRI was 
thought to be helpful in surgery and to improve outcome so that it seemed unethical to 
perform surgery without iMRI in part of the study population. Pure endoscopic treatment of 
pituitary adenomas was not performed during the time of this study so that there is no 
group of patients for comparison of the results within the same center. This is especially a 
drawback as comparison to previously published series is complicated as not only the 
surgical method but also pre- and postoperative study protocols differ widely. 
 
Although the iMRI was useful and lead to improved remission rates and improved 
endocrinological- and neurological outcome there are some drawbacks in ultra-low field 
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iMRI to consider as well. Even if studies failed to show better results in surgical series 
using intraoperative high field MRI, image quality and resolution is - at least theoretically – 
better than in ultra-low field MRI (23,41). Costs for intraoperative imaging are still high due 
to installation, maintenance and time loss during surgery. Studies with larger patient 
numbers and cost/risk analysis should address the question whether better clinical and 
endocrinological outcome can compensate for these increasing costs.  
 
 
7. Conclusions: 
Data from this largest study to date analyzing general postoperative outcome and pituitary 
function in patients undergoing ultra-low-field iMRI-assisted microsurgical treatment of 
PAs show that the presented method is a safe and highly effective treatment option. The 
results are at least as good as those reported in previously published series – even in 
those with use of high-field iMRI or endoscopy. iMRI appeared to increase the rate of 
remission while keeping the complication rate low. Postoperative pituitary function was 
usually preserved and even improved in around 17% of the patients - possibly due to 
more exact and more extended iMRI-assisted tumor removal. This is not only a great 
achievement for each individual patient but also an important socioeconomic factor as 
hormone substitution therapy is expensive and health care systems worldwide face 
increasing budget deficits. 
15 
 
8. Table and figure legends 
 
Table 1: Study and patients characteristics 
Table 2: Pre-,intra- and postoperative imaging 
Table 3: Mean pre-/postoperative hormone levels 
Table 4: Characteristics of 62 patients with preoperative hypopituitarism: Type of 
  deficiencies and replacement therapy before and after surgery 
Table 5: Endocrine outcome of patients grouped according to Hardy’s classification 
 
Illustrative case: Preoperative, intraoperative and postoperative imaging 
Figure A: Preoperative MRI, coronal view, contrast enhanced 
Figure B: Intraoperative MRI, coronal view, contrast enhanced, before skin incision 
Figure C: Intraoperative MRI, coronal view, contrast enhanced, during resection 
Figure D: Intraoperative MRI, coronal view, contrast enhanced, before closure 
Figure E: Postoperative MRI, coronal view, contrast enhanced 
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Table 1: Study and patients characteristics 
 
Number of patients 145 
Number of operations 148 
Sex (male/female) 82 / 63 (56.6% / 43.4%) 
Mean age in years 55 ± 15 (19-80) 
Mean preoperative tumor size in mm3 6797 (50–65,450) 
Infiltration of cavernous sinus 51 (35.7%) 
Patients with microadenoma 10 (6.9%) 
Patients with macroadenoma 118 (82.5%) 
Patients with giant adenoma 15 (10.5%) 
Patients with previous surgery 24 (16.8%) 
Patients with cranial nerve symptoms 89 (62.2%) 
Patients with visual field deficits 79 (55.2%) 
Patients with pan-/hypopituarism 62 (41.9%) 
Patients with preop. hormone substitution 29 (17.5%) 
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Table 2: Pre-,intra- and postoperative imaging 
 
Preoperative tumor size in mm3 6797 (50-65,450) 
Infiltration of cavernous sinus 51 (35.7%) 
Intraoperative imaging p.pt. 2.51 ± 0.99 
Intraoperative additional tumor removal 56 (37.8%) 
Mean follow up in month 32 (4-62) 
Postoperative tumor remnant in mm3 42 (28.4%) 
Mean Size of tumor remnant in mm3 1191 (4-15559) 
Patients being in remission 101 (68.2%) 
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Table 3: Mean pre-/postoperative hormone levels 
 
 preoperative postoperative 
Cortisol in nmol/l 393 (3-1640) 349 (9-808) 
TSH in mU/l 1.73 (0.01-6.96) 1.72 (0.01-6.12) 
fT4 in pmol/l 13.80 (5.60-20.30) 15.35 (4.00-25.40) 
GH (NFPA pts only) in µg/l 0.59 (0.05-4.88) 1.21 (0.08-5.55) 
IGF1 (NFPA pts only) in µg/l 102 (31-492) 101 (29-209) 
Prolactin in µg/l 25.07 (0.50-109.50) 15.38 (0.50-227.00) 
FSH (female pts only) 21.86 (0.10-92.00) 27.69 (1.20-95.90) 
LH (female pts only) 9.29 (0.10-43.90) 12.78 (0.10-48.20) 
Testosteron (male pts only) in nmol/l   
 
 
 
